USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Schott Pharma Ag & Co. KGAA

USPTO PatentsView assignee record - 23 granted patents across 16 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ).

23
Total patents granted
16
CPC technology areas
18.5
Avg claims per patent
-
5-year filing velocity

The verdict

Schott holds 23 US patents across 16 technology areas, rank #13,133 of 50,000 tracked assignees.

#13,133
of 50,000 US assignees by volume
Top 6%
by Innovation Score (56.2/100)
18.5
avg claims per patent

Portfolio overview

SCHOTT PHARMA AG & CO. KGAA has been granted 23 US utility patents between 2023 and 2025, placing SCHOTT PHARMA AG & CO. KGAA at rank #13,133 across all assignees tracked by PlainPatent. This portfolio spans 16 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.5 claims per patent with primary concentration in A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ). As a Foreign Corporation, SCHOTT PHARMA AG & CO. KGAA is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 56.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 23 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. SCHOTT PHARMA AG & CO. KGAA's 18.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 16 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark SCHOTT PHARMA AG & CO. KGAA against peers pursuing similar technology classes.

How does SCHOTT compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows SCHOTT holds 23 patents, placing it at rank #13,133 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

SCHOTT's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

56 Top 6% higher than 94% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

6.577.588.5 202320242025 7
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
SCHOTT PHARMA AG & CO. KGAA patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 8 34.8%
2024 8 34.8%
2025 7 30.4%

Which technologies does SCHOTT PHARMA AG & CO. KGAA patent most?

Top 15 of 16 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard

Where it ranks

Overall rank by patents

#13,133

Across all tracked assignees

Innovation Score

56.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does SCHOTT PHARMA AG & CO. KGAA hold?
SCHOTT PHARMA AG & CO. KGAA holds 23 US granted patents filed between 2023 and 2025, spanning 16 technology areas.
What is SCHOTT PHARMA AG & CO. KGAA's Innovation Score?
SCHOTT PHARMA AG & CO. KGAA has an Innovation Score of 56.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does SCHOTT PHARMA AG & CO. KGAA focus on?
SCHOTT PHARMA AG & CO. KGAA's top technology area is A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE) with 14 patents. The company has filed patents in 16 CPC subclasses total.
Is SCHOTT PHARMA AG & CO. KGAA's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for SCHOTT PHARMA AG & CO. KGAA.
What does claim depth mean for SCHOTT PHARMA AG & CO. KGAA's patents?
SCHOTT PHARMA AG & CO. KGAA's patents average 18.5 claims each. This falls within the standard range, providing solid legal coverage.
How is the SCHOTT PHARMA AG & CO. KGAA patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Guides to patent portfolio analysis

How to use this portfolio

Schott's 23 grants land it in the top 6% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Schott ranks #13,133 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61J - see who else leads that technology area. A61J leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov